13F Holdings
中文EN

ADAPY Adaptimmune Therapeutics PLC

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1621227 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-54.0%
TTM net income YoY-134.1%
TTM EPS YoY-83.3%
Revenue 3-yr CAGR77.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-252.3%
Net margin-260.8%
FCF margin-294.5%
EBITDA margin-237.0%

Returns

ROE-1,341.1%
ROA-75.1%
ROIC (approx.)—
Asset turnover0.29x

Leverage & solvency

Liabilities / assets154.3%
Debt / equity—
Current ratio1.52x
Interest coverage-28.99x

Cash quality & payout

Operating cash flow / net income1.12x
Accruals ratio9.0%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31
Income statement
Revenue$178.03M$60.28M$27.15M$6.15M$3.96M
Cost of revenue$70,000————
Gross profit$177.96M————
R&D expense$149.06M$126.51M$127.73M$111.09M$91.57M
SG&A expense$87.26M$73.51M$63.39M$57.30M$45.80M
Operating income-$68.76M-$139.74M-$163.97M-$162.25M-$133.41M
Interest expense$3.35M————
Pretax income-$67.24M-$112.53M-$162.96M-$157.30M-$129.93M
Income tax$3.58M$1.34M$2.50M$791,000$162,000
Net income-$70.81M-$113.87M-$165.46M-$158.09M-$130.09M
EBITDA-$57.95M-$130.29M-$158.70M-$156.62M-$126.78M
EPS (basic)-0.05-0.09-0.17-0.17-0.15
EPS (diluted)-0.05-0.09-0.17-0.17-0.15
Weighted avg. shares (diluted)1.51B1.21B967.24M934.83M854.78M
Balance sheet
Cash & equivalents$91.14M$147.02M$109.60M$151.67M$61.48M
Short-term investments$60.47M$2.95M$96.57M$219.63M$311.33M
Receivables$1.45M$821,000$7.43M$752,000$139,000
Inventory$7.32M————
Current assets$188.17M$207.55M$255.37M$415.46M$398.15M
PP&E, net$31.31M$50.95M$53.52M$30.49M$27.78M
Intangibles$3.88M$330,000$442,000$1.00M$1.73M
Total assets$245.96M$282.62M$328.92M$469.55M$451.14M
Current liabilities$64.53M$72.79M$64.50M$62.54M$39.07M
Long-term debt$50.24M————
Total debt$50.24M————
Total liabilities$234.11M$243.10M$247.04M$263.58M$109.92M
Shareholders' equity$11.85M$39.51M$81.88M$205.96M$341.23M
Net debt-$40.90M————
Shares outstanding1.54B1.36B987.11M928.55M928.75M
Cash flow statement
Operating cash flow-$73.21M-$140.88M-$141.77M$10.73M-$53.59M
Capital expenditure$886,000$4.68M$29.50M$8.57M$2.34M
Free cash flow-$74.09M-$145.56M-$171.26M$2.15M-$55.93M
Investing cash flow-$58.95M$176.54M$89.14M$75.80M-$278.92M
Financing cash flow$78.75M$880,000$12.87M$3.29M$340.05M
Depreciation & amortization$10.81M$9.45M$5.27M$5.63M$6.63M
Stock-based compensation$12.05M$11.77M$18.24M$20.63M$10.41M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.